🔥off the press: Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Annals of Oncology doi.org/10.1016/j.anno… 👉get the lastest update on HCC management 👉Multiple options > MDT is key ESMO - Eur. Oncology EASL Education ILCA #livertwitter

Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† - Annals of Oncology annalsofoncology.org/article/S0923-…

Does immunotherapy in #SCLC delay brain metastases? Retrospective report Lung Cancer Journal on 550 pts show pts treated with atezolizumab + carbo/etop longer time to intracranial progression: 24.4 vs 14.3m and if no PCI: 27.2 vs 15.2m. Improved PFS and OS. lungcancerjournal.info/article/S0169-…

Here is what happened when SBRT was delivered to all sites of visible disease in 17 patients with metastatic NSCLC receiving a combination of dual checkpoint inhibitors (CTLA4 and PDL1). Only 1 had an SBRT-related G3+ adverse event. Ticiana Batista (Leal)

🚀 SBRT vs. Surgery for Pulmonary Metastases in Colorectal Cancer – What’s the Best Local Therapy?OncoAlert 🎯 Objective: •Compare local control and toxicity of SBRT vs. wedge resection in colorectal pulmonary metastases. 🏥 Methods: •Retrospective study of 404 👥 (528

Our incredible GI leaders paving the path for EBRT in HCC. Published in The Lancet Gastroenterology & Hepatology “Compelling new randomised controlled trial results support that future hepatocellular carcinoma guidelines should include EBRT”. See figure. Stephanie Dudzinski MD, PhD, you’re a superstar!

SBRT para HCC!!! # linkedin.com/posts/matthias…

📢 ¡No te pierdas la mesa ASTRO/ESTRO! 🌍🔬 En el 4.º Congreso Iberoamericano: Lo Mejor en Cáncer de Pulmón 2024,destacados expertos Rodolfo Chicas-Sett José Luis López Guerra nos presenta los últimos avances en radioterapia para el cáncer de pulmón, moderados por el Dr. Jorge Palazzo. #CLICaP 🫁

1/ 🧨 OMET trial (GORTEC 2014-04) in oligometastatic HNSCC 👥 N=69, SABR alone vs SABR + chemo + cetuximab 🧪 Key finding: Similar 1-year OS without ⬇️QoL (SABR 55.2% vs chemo-SABR 53.3%). 🏆SABR alone had⬇️toxicity and QoL impact. 📉 Gr 3–4 tox: 8.8% (SABR alone) vs 60% 🧵

Se está celebrando la I Jornada de la Plataforma Interdisciplinar de Investigación Traslacional en Oncología Radioterápica

Concluye la Jornada. Muchas gracias a todos!!👏👏

[1/5] Buenas noticias para pacientes con #CáncerDePróstata recurrente. Nuestro equipo de Oncología Radioterápica ha participado en el ensayo PEACE V–STORM, recién publicado en The Lancet Oncology. Te contamos por qué es importante. #Oncología #Radonc Dr. Antonio J. Conde HospitalLaFe

Wow, this trial showed no OS benefit to FOLFIRINOX vs. single agent gemcitabine in locally advanced pancreas cancer (different than adjuvant & metastatic trials - both w OS improvement!) PFS increased by 2 mo, but this came at cost of increased toxicity, $, treatment burden.

4ª Masterclass #Radioterapia en Cáncer de Pulmón ➡️Protonterapia: un horizonte al alcance 📆Jueves 22 de mayo ℹ️goecp.seor.es

💥 Moderamos MasterClass sobre Protonterapia en cáncer de pulmón 💥 🎤 Ponentes🔝: 👩‍⚕️ Dra. Núria Rodg de Dios – Santiago de Compostela 🏥 Innovación 👨‍⚕️ Dr. Jacobo Palma – Clínica Universidad de Navarra ✔️ Indicaciones 👨‍🔬 Sr. Juan Castro – quirónsalud💡Aspectos físicos Discusor: Dr Rodolfo Chicas-Sett #SomosHUVR

❗️ Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer (ACHILES) HR 1.14 (0.76-1.71) 👎 and makes me wonder re: ADRIATIC as well 🤔 #ASCO25

🚨NEW in CA: A Cancer Journal for Clinicians: A comprehensive review of advances in hepatocellular carcinoma (#HCC) therapy. From surgery to IR to SBRT to immunotherapy, this is your clinical update 🧵 Dr. Nina Niu Sanford Neil Newman Krishan Jethwa Amir Safavi Laura Dawson A.Allam Mohamed Freddy E Escorcia (@freddyeescorcia elsewhere) M. Bolton

Excited to be a part of this collaboration with friends and colleagues in Amsterdam. It isn't inspired entirely to advance SABR in place of surgery; instead, it is about identifying how often adrenalectomies end up with positive margins and local recurrence. The preliminary data

With this being the case, makes it difficult to endorse surgery for any of these stage IA lung cancers. SBRT or ablation is likely more than sufficient. Scott Oh Catherine L. Oberg, MD AABIP

📢 New in European Urology: SABR is not just for brain mets. A systematic review shows excellent results in RCC—alone or with IO. 🧠 Local control in primary RCC 🛡️ Delay of systemic therapy in oligomets ⚡ IO + SABR: promising combos 🔗 buff.ly/5XN3Ejr #RCC #SABR